Friday, January 25, 2019
AbbVie says 2018 results ‘well above expectations’
Says: Biosimilar competitors have been more aggressive… Expects to absorb $2B of erosion in 2019 from biosimilar competition… Expects to deliver “positive” revenue growth in 2019… Pleased with investment strategy… Saw “significant” pipeline advancement in 2018. Comments from Q4 earnings conference call.
https://thefly.com/landingPageNews.php?id=2853857
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.